Investment
Features
FeesSafety
Academy
More
Pluang+

Alnylam stock plunges after cutting 2026 sales forecast and facing legal probe.

Market News
28 Aug 2026
Gordon Thompson
View Source
Bearish
pluang ai news

Alnylam Pharmaceuticals saw its stock drop sharply after it lowered its 2026 sales guidance by about $200 million due to slower demand for its TTR products. Despite a strong biotech sector, Alnylam's shares fell by $81.14 per share, losing about 25% of its value since late July. This decline has triggered a legal investigation into possible securities law violations by the company or its management. The stock currently trades around $232.84 with a market cap of $31.16 billion, showing significant volatility over the past year.

More News (ALNY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App